perpetuity. All rights reserved. No reuse allowed without permission.

1 Early diagnosis of transthyretin amyloidosis by detection of monomers in

2 plasma microsamples using a protein crystal-based assay

3

4 Diogo Costa-Rodrigues^{a,b,c}, José P. Leite^c, Maria João Saraiva^{a,b}, Maria Rosário Almeida^{a,b,c},

- 5 Luís Gales^{a,b,c*}
- 6

7 ^a i3S – Instituto de Investigação e Inovação em Saúde, Rua Alfredo Allen, 208, Porto, Portugal

^b IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen, 208, Porto,
 Portugal

10 ^c ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Rua de Jorge Viterbo Ferreira 228, Porto, Portugal

11 * corresponding author: E-mail: <u>lgales@ibmc.up.pt</u>

12

13 Abstract

14 Amyloid diseases are frequently associated with the appearance of an aberrant form of a

protein, whose detection enables early diagnosis. In the case of transthyretin amyloidosis,

- 16 the aberrant protein the monomers constitute the smallest species of the amyloid
- 17 cascade, which creates engineering opportunities for sensing that remain virtually
- unexplored. Here, a two-step assay is devised, combining molecular sieving and
- immunodetection, for quantification of circulating monomeric transthyretin in the plasma. It
- is shown that mesoporous crystals built from biomolecules can selectively uptake
- 21 transthyretin monomers up to measurable quantities. Furthermore, it was found that the use
- of endogenous molecules to produce the host framework drastically reduces unspecific
- adsorption of plasma proteins at the crystal surface, a feature that was observed with metal-
- organic frameworks. The assay was used to analyse plasma microsamples of patients and
- 25 healthy controls. It shows a significant increase in the levels of monomeric transthyretin in
- 26 the patients, proving its usefulness to establish the monomers as soluble and non-invasive
- 27 marker of the disease. In addition, the assay can evaluate transthyretin stabilizers, an
- 28 emergent strategy that broadened the treatment approach to the disease. Sensing the initial
- 29 event of the transthyretin amyloid cascade with the proposed assay can make the difference
- 30 for early diagnosis and eliminate the currently adopted invasive biopsies modalities for
- 31 detection of the final products of the aggregation pathway.

32

33 Keywords: amyloid biomarkers; transthyretin monomers; sensors; molecular sieves; protein

34 crystals; MOFs

35 1. Introduction

Transthyretin related amyloidosis (ATTR) is a highly debilitating and life-threatening disease. Significant variations in phenotypic and genotypic expression of the disease hamper early and accurate diagnosis which delays initiation of appropriate treatment (Adams et al. 2016). Current diagnostic methods include tissue biopsy analysis to detect amyloid deposits and genetic tests to search for TTR mutations. However, the disease can be associated with deposition of wild-type TTR in the myocardium which cannot be diagnosed by TTR sequencing.

43 Biopsy tests are focused on the observation of the final products of the amyloid 44 cascade. Patients carry less stable TTR homotetramers that are prone to dissociation into non-native monomers, which in turn rapidly self-assemble into oligomers and, ultimately, 45 amyloid fibrils. New methods for precise monitoring of the initial steps of the amyloid 46 47 cascade, i.e. monomeric TTR levels in the plasma, are crucial to evaluate new 48 pharmacological advances that broadened the treatment approach to ATTR, such as 49 stabilizers of the native tetrameric TTR structure (Almeida et al. 2005) and antisense 50 oligonucleotides that inhibit the hepatic production of TTR (Benson et al. 2018; Gales 2019).

Here, we devised a mesoporous crystal–based assay for selective extraction of TTR monomers over the native tetramers for posterior immunodetection (Fig. 1). The crystals work as sponges that enrich small proteins (including monomeric TTR) from a mixture, up to measurable quantities. By leveraging the molecular sieving properties of the mesoporous crystals and reducing unspecific surface adsorption of plasma proteins we developed an assay for accurate discrimination between the levels of circulating monomeric TTR in ATTR patients and healthy individuals.

58 Crystals with high density of single sized pores are excellent candidates to separate mixtures of compounds with similar molecular sizes. Two different types of crystals were 59 60 tested: protein crystals and Metal-Organic Frameworks (MOFs). A few researchers have been calling attention to protein crystals as microporous materials that offer a wide range of pore 61 size (sometimes exceeding 10 nm), porosity (0.5-0.8), and pore surface area (800-2000 $m^2.g^-$ 62 ¹) (Vilenchik et al. 1998). Protein crystals are mostly produced to collect X-ray diffraction data 63 to determine the atomic structure of the constituent molecules. Structural biologists are 64 65 often insensible to the remarkable potential of such particles for engineering applications.

Despite being soft and fragile solids that quickly dissolve in unfavourable environments,
chemical cross-linking makes protein crystals much more stable, with little change in pore
structure.

The most common strategies employed to adjust pore dimensions are size selection of 69 70 the host protein and targeting specific network topologies. Several crystalline frameworks have been constructed with those strategies displaying a large range of pores, from 71 72 subnanometer channels achieved by the assembly of short hydrophobic dipeptides (Görbitz 73 2001) up to proteins that self-assemble into 750 kDa cube-shaped cages with 13 nm inner 74 cavities (Lai et al. 2014). The crystals have been used as scaffolds to investigate the diffusion in confined environments of small (Durão and Gales 2013) and large (Cvetkovic et al. 2005) 75 76 guest molecules or as hosts to uptake compounds ranging from gas molecules (Afonso et al. 2010; Comotti et al. 2009) to biomacromolecules (Hashimoto et al. 2019). Among the 77 biomolecules of interest to encapsulate are enzymes (Kowalski et al. 2019) whose stability is 78 79 thereby enhanced. Another interesting field is the engineering of self-assembled porous protein crystals in living cells, aiming applications such as molecular recognition and storage 80 81 of exogenous substances (Abe et al. 2017).



- Fig. 1. Schematic representation of the transthyretin amyloid cascade. Tetramer dissociation
 is the rate-limiting step. Emergent therapeutic strategies inhibition of the synthesis of the
 protein and stabilization of the native protein are pointed. Mesoporous materials will be
 used here for extracting the monomeric TTR species from plasma samples for subsequent
 immunosensing.
- 88

89 There are not many other crystalline materials that can reach sufficiently wide pores to encapsulate macromolecules. Another example is the class of MOFs. MOF materials are 90 being developed for several biomedical applications, such as drug delivery, protection of 91 biomolecules and cells, phototherapy and sensing (Mendes et al. 2020). In particular, MOF 92 sensors perform at least as well as standard methods for many biomarkers (Dong et al. 2020; 93 Gu et al. 2020; Sheta et al. 2019; Song et al. 2020; Wang et al. 2019; Wu et al. 2020; Zhou et 94 al. 2018), including several amyloid related agents such as amyloid β peptide, α -synuclein, 95 insulin, procalcitonin and prolactin (reviewed in (Leite et al. 2023; Tajahmadi et al. 2023)). 96 These sensors reduce the overall complexity of currently used protocols, making them more 97 appealing for a clinical setting. However, there is a focus in Alzheimer's disease monitoring in 98 detriment to other amyloidosis that are clearly under studied despite their relevance (e.g. 99 100 Parkinson's disease) or not explored at all (e.g. TTR amyloidosis) (Leite et al. 2023). Interestingly, in this work MOFs were not used as co-adjuvant materials as in most 101 102 applications in construction of amyloid sensors but rather as a molecular sieve for extraction 103 of the analyte.

104

105

106 2. Experimental Section

107

108 2.1. Materials

Thermolysin from *Geobacillus stearothermophilus* was purchased from Sigma-Aldrich
 (Type X, lyophilized powder, 30-350 units/mg protein (E1%/280)), resuspended as previously
 described (Hausrath and Matthews 2002) and used without further purification. Cytochrome
 c from bovine heart (≥95%) was purchase from Sigma-Aldrich. Terbium nitrate pentahydrate
 and 4,4',4"-s-triazine-2,4,6-triyl-tribenzoic acid (H3TATB) were also purchased from Sigma Aldrich (UK). All other reagents were of analytical grade.

115

116 2.2. Recombinant human TTR

117 TTR wild-type (TTR WT) and variants were produced using a bacterial expression
118 system and purified as previously described (Furuya et al. 1991). Recombinant TTR was

dialyzed against endotoxin-free phosphate-buffered saline (PBS), concentrated using Vivaspin
ultrafiltration units (GE Healthcare, Chicago, IL, USA), and quantified using Bradford protein
assay (Bio-Rad, Hercules, CA, USA).

122

123 2.3. Plasma Samples

The utilization of «human blood samples from individuals who requested to perform blood collection with predictive character at the Center for Predictive and Preventive Genetics (CGPP) of the IBMC to evaluate the condition of the pre-symptomatic V30M mutation» was submitted by the group Molecular Neurobiology (i3S) and approved by the Ethical Committee of the University of Porto (Report n°36/CEUP/2017).

129

130 2.4. Synthesis of Tb-MOF

Tb-MOF was synthesized as described in (Leite et al. 2019) which was adapted with minor modifications from (Park et al. 2007). Briefly, terbium nitrate (1.38×10^{-4} mol) and 4,4',4"-s-triazine-2,4,6-triyl-tribenzoic acid (4.54×10^{-4} mol) were dissolved a mixture of dimethylacetamide/methanol/water (4.0/0.8/0.2 mL, respectively). The solution was heated to 378 K for 48 h in a scintillation vial and then slowly cooled to ambient temperature. Colourless octahedral crystals were clearly visible.

137

138 2.5. Synthesis of cross-linked thermolysin crystals (TLN-CLC)

Tetragonal crystals were grown according to the method described in (Leite and Gales 139 2019), using the hanging drop vapour diffusion method in 24-well crystallization plates at 140 20°C. In each well, 500µl of 1M ammonium sulphate was added to the reservoir as 141 precipitant solution. A drop of 6μ l was added to the cover slide; its composition was 50% v/v 142 of 150 mg·ml⁻¹ thermolysin dissolved in 45% DMSO, and 50%v/v of 1M zinc chloride also 143 dissolved in 45% DMSO. After ~24h the presence of crystals was confirmed. Crystallization 144 145 conditions were carefully controlled to obtain reproducible crystals. Crystal cross-linking: one drop of 1µl of 25% v/v glutaraldehyde was added directly to the crystal's drop. The well was 146 147 then closed again (well-sealed with grease to avoid vaporization of glutaraldehyde), and the crystals were left incubating ~1h30min. 148

149

150	2.6. Analysis of the monomeric TTR extraction by the mesoporous crystals using SDS-PAGE.
151	10 mg of MOF crystals were incubated overnight with recombinant TTR at 0.2 mg.ml ⁻¹
152	(150 μ l sample volume) in PBS 1x, pH 7.4. Crystals were washed to remove superficially
153	adsorbed protein, dissolved by gentle heating and acidification and resuspended in 50 mM
154	HEPES pH 7.5. Samples were analysed in 15% (w/v) polyacrylamide gels by SDS-PAGE.
155	NZYColour Protein Marker II (NZYtech) was used as a molecular weight marker. The same
156	procedure was used with TLN-CLC but with a sample of five crystals.
157	
158	2.7. Analysis of the monomeric TTR uptake by TLN-CLC using molecular probes cytochrome c

- 159 and fluorescein
- 160 Single TLN-CLC crystals were incubated at RT, for 3 h, in 5 μl drops of TTR (3.6x10⁻⁶ M in
- 161 phosphate buffered saline pH 7.4). The void volume of the crystals, which is expected to
- 162 diminish by the uptake of TTR monomers, was estimated by two methods, schematically
- 163 presented in Fig. 2.

164



- 166 Fig. 2. Schemes of the experimental procedure for estimation of the free void volume of the
- 167 TLN-CLC crystals after TTR uptake, with fluorescein (A) and cytochrome c (B).
- 168
- Method 1 (Fig. 2A): 2 μl of a solution of 1mM fluorescein was added to the crystal drop
 and incubated for 2 hours. The crystals were then fish out using a nylon loop, gently placed in
 a clean surface to remove the solution in the loop and transferred, also with a loop, to a

phosphate buffered saline solution. Fluorescence was measured after 18h (Excitation at 494
nm and emission at 521 nm).

Method 2 (Fig. 2B): 10 μl of a solution of cytochrome c (5 mg.ml⁻¹) was added to the
crystal drop and incubated for 18h. The crystals were fished out with a nylon loop, quickly
passed through a washing solution, and transferred to a reader plate to record a cytochrome
c catalysed colorimetric reaction. Peroxidase activity was determined using 3,5',5,5'-

tetramethylbenzidine (TMB) as described in (Parakra et al. 2018). Briefly, cytochrome c

samples in the presence of TMB (1.6 mM) were reacted with H_2O_2 (300 μ M) in phosphate

180 buffer (pH 5.4, 80 mM), at room temperature. TMB oxidation was follow measuring the

absorbance at 652 nm and the initial velocity of the reaction determined.

182 Three independent experiments were performed for each condition. The morphology 183 of TLN-CLC crystals was very homogeneous, which was confirmed by optical imaging of the 184 crystals and by measuring their fluorescein adsorption capacity.

185

186 2.8. TLN-CLC based assay for evaluation of TTR drug candidates.

187 Recombinant TTR samples were incubated overnight with tafamidis or acoramidis at 188 molecular drug/TTR ratios of 10/1, 1/1 and 0/1. Then, the procedure described in section 2.7 189 was followed. Three independent experiments were performed for each condition.

190

191 2.9. TLN-CLC based assay for analysis of plasma samples.

Three TLN-CLC crystals were incubated three hours at RT in 5 μl drops of plasma
samples. The uptake of TTR monomers, was evaluated by immunoassay analysis, namely
Western Blot and ELISA.

Western Blot: After incubation the crystals were fished out using a nylon loop, gently
placed in a clean surface to remove the solution in the loop and transferred, to a PBS
solution. SDS-PAGE analysis was performed (15% (w/v) polyacrylamide gels) and the proteins
transferred onto nitrocellulose membranes. The membranes were blocked with 5% skim milk
in PBS with Tween 20 (PBST), for 1 h at room temperature. Next, the membranes were
incubated overnight at 4 °C, with a rabbit polyclonal antibody against human TTR (DAKO) at a

1:500 dilution. The membranes were washed three times in PBST for 5 min and were then
incubated with a secondary antibody, conjugated with HRP (Goat anti-rabbit IgG, at a
1:10000 dilution) for 1 h at room temperature. Protein bands were detected via the
enhanced chemiluminescence technique, using the Clarity ECL detection kit (BIO-RAD). Four
independent experiments were performed for each condition.

ELISA: For determination of TTR inside the crystals, rabbit polyclonal anti-human TTR antibody (DAKO) was used as capture antibody at a 1:500 dilution, sheep anti-human TTR (Abcam) antibody diluted at 1:2500, as secondary antibody, and lastly was used donkey antisheep antibody (SIGMA) in a dilution of 3:10000. SIGMAFAST (p-nitrophenyl phosphate tablets) were used and absorbance was determined at 410 nm. Three independent experiments were performed for each condition.

212

213 2.10. Mass spectrometry (protein gel band, figure 3E).

214 Peptide cleavage characterization was performed by nanoLC–MS/MS, with a Ultimate 3000 liquid chromatography system coupled to a Q-Exactive Hybrid Quadrupole-Orbitrap 215 mass spectrometer (Thermo Scientific, Bremen, Germany). Samples were loaded onto a 216 trapping cartridge in a mobile phase of 2% ACN, 0.1% FA at 10 μ L·min⁻¹. After 3 min loading, 217 the trap column was switched in-line to a reverse phase column at 300 nL·min⁻¹. Separation 218 219 was performed with a gradient of 0.1% FA (A) 80% ACN, 0.1% FA (B). The mass spectrometer 220 was operated in a Full MS positive acquisition mode. The ESI spray voltage was 1.9 kV. The global settings were use lock masses best (m/z 445.12003), lock mass injection Full MS, 221 chrom. peak width (FWHM) 30s. The full scan settings were 70k resolution (m/z 200), AGC 222 target 3 × 106, maximum injection time 200 ms, scan range: 400–4000 m/z. 223

224

225 2.11. Statistical analysis.

Data was analysed using GraphPad Prism Software (version 9.5.0). Unpaired *t*-test with
Welch's correction was performed. Levels of statistical significance at * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001 were used. The number of independent experiments
performed is given above, in the description of the respective assay.

230 3. Results and discussion

231

3.1. Tb-MOF separate TTR monomers from tetramers in vitro but are prone to unspecific
 surface adsorption of plasma proteins

234 Initial screening for MOFs capable of tailored uptake of TTR monomers and exclusion of tetramer led us to select Tb-MOF (Fig. 3A), a robust material, stable in several solvents, that 235 236 has cages of 3.9 and 4.7 nm (Park et al. 2007). Screening consisted in the incubation of MOF crystals (10 mg) in samples of pure recombinant TTR variants (0.2 mg.ml⁻¹, 150 μl), including 237 the wild-type protein (TTR-WT) and two highly amyloidogenic variants: TTR-L55P (Bonifácio 238 et al. 1996) and TTR-Y78F (Redondo et al. 2000). Crystals were then dissolved and analysed 239 240 by SDS-PAGE. TTR was detected in all TTR soaking solutions, as expected (Fig. 3B). Crystals that were pre-incubated with the amyloidogenic variants TTR-L55P and TTR-Y78F 241 encapsulated measurable quantities of monomeric TTR, while crystals soaked with TTR-WT 242 243 did not. The amyloidogenic variants are less stable, more prone to dissociate into monomeric 244 species that penetrate in the MOF framework.

245 The promising results obtained with pure recombinant TTR solutions prompted us to investigate the detection of TTR monomers in plasma samples of ATTR patients carrying TTR-246 247 V30M, the most frequent TTR variant associated with amyloidosis worldwide, found endemically in the northern parts of Sweden, and in regions of Portugal and Japan. We 248 249 observed that a mixture of low molecular weight plasma proteins penetrates in the Tb-MOF framework, which was further separated by gel electrophoresis (Fig. 3C). The gel band with 250 251 the expected molecular weight of the TTR monomer was excised and analyzed by mass 252 spectrometry. TTR-V30M patients are heterozygotes and, accordingly, both the TTR-WT and the TTR-V30M monomer were identified (Fig. 3D). 253

Unfortunately, inspection of the crystals in contact with plasma samples with a stereomicroscope reveals the formation of a layer at the surface of the crystals composed by plasma proteins which may include tetrameric TTR. This external protein layer is hard to separate from the smaller protein species that occupy the crystal cages. Consequently, SDS electrophoresis of the dissolved crystals shows high molecular weight protein bands (Fig 3E). Since it is crucial that the protein extract doesn't become contaminated with tetrameric TTR, we decided to test other types of mesoporous crystals built with biomolecules – protein

261 cross-linked crystals – with the expectation that they are less prone to surface adsorption of

262 plasma proteins.

263

264



265

Fig. 3. Analysis of the protein extracted from recombinant TTR samples and from plasma 266 samples by Tb-MOF crystals. A. Optical image of Tb-MOF crystals (scale bar 0.5 mm). B. SDS 267 analysis of the dissolved crystals after protein extraction from pure samples of recombinant 268 TTR. Results shown for the TTR WT and for the amyloidogenic variants TTR-L55P and TTR-269 270 Y78F (Sol. - protein soaking solution and Crystal - protein extracted from the crystals 271 dissolved after incubation with the soaking solutions). Tb-MOF extracted observable quantities of protein from the amyloidogenic variants, but not from the TTR WT (mostly 272 273 tetrameric). C. SDS-PAGE gel of the protein extract from the plasma sample of a TTR-V30M carrier using Tb-MOF. The band \approx 14kDa (approximate MW of the TTR monomer), 274 highlighted in the figure, was excised and analysed by mass spectrometry, confirming it as 275 276 TTR (D). E. SDS-PAGE gel of plasma proteins that become adsorbed at the external surface of 277 Tb-MOF crystals, after 30 min and 1 h of incubation time with TTR-V30M and TTR-WT plasma 278 samples. Size-excluded proteins become adsorbed which reduces the separation efficiency of the crystals. 279

3.2. Thermolysin cross-linked crystals (TLN-CLC) separate TTR monomers from tetramers in vitro

283 TLN crystals grow in two main packing systems, hexagonal and tetragonal. These 284 distributions can be achieved by modifying one component of the mixing solution: zinc 285 (Hausrath and Matthews 2002). When grown in media that contain the ion (for example zinc 286 chloride or zinc acetate), the crystals adopt a tetragonal packing system. In contrast, if the 287 solution does not contain zinc, the packing will be hexagonal (Leite and Gales 2019). Tetragonal crystals are more uniform and have a solvent content of 66% (Fig. 4A). Hexagonal 288 289 crystals are longer and rod-like and have a solvent content of 46% (Juers et al. 2018). Owing 290 to the desired application of the crystals, the packing system of greatest interest is the 291 tetragonal because it displays one-dimensional channels with appropriate dimensions along 292 the c-crystallographic axis. Soakability predictions of crystal channels using MAP CHANNELS (Juers and Ruffin 2014) and LifeSoaks (Pletzer-Zelgert et al. 2023) provided an overall 293 294 bottleneck radius of 1.7 nm and a maximum pore radius of 2.0 nm. The surface of the TLN 295 crystal channels show an overall hydrophobic environment and display only weak and localised charges. The target protein, TTR, in the native tetrameric form has a maximum 296 297 dimension of 7.0 nm. Despite the lack of information about the structure and flexibility of monomeric TTR, the channel dimensions make tetragonal TLN crystals good candidates for 298 299 extraction of the TTR monomeric species and size-exclusion of the tetramers (Fig. 4B). Furthermore, it is known that TTR dissociation exposes hydrophobic regions in the monomer 300 301 surface (Kim et al. 2016) which probably drives diffusion from the bulk solution and 302 potentiate pore entrapment; accordingly, the low charged surface of TLN channels generate 303 an amenable chemical environment for uptake of TTR monomers.

304 The packing of the grown crystals was confirmed by single crystal X-ray diffraction using an in-house equipment (Rigaku/Oxford Diffraction Gemini PX Ultra single-crystal X-ray 305 306 diffractometer). Crystals were then cross-linked with glutaraldehyde, incubated with five recombinant TTR variants and then the protein uptake from each sample was analysed. The 307 308 five TTR variants tested were three amyloidogenic mutants, TTR-Y78F, TTR-L55P and TTR-V30M, the TTR-WT and one variant with protective effect TTR-T119M (Almeida et al. 2000). 309 310 Western blotting analysis using an antibody targeting human TTR shows that TTR uptake is higher for TTR-Y78F, TTR-L55P and TTR-V30M than for TTR-WT and TTR-T119M, and thus 311 that it correlates with TTR quaternary instability (Fig 4C). The fact that TTR-T119M which is 312

even more stable than TTR-WT is hardly detected gives a clear indication that the native TTR
tetramer does not penetrate in the TLN-CLC framework.

315 In addition, we developed a cheaper alternative strategy to the use of anti-TTR antibodies to access the crystal extraction from pure recombinant TTR samples. Uptake of 316 317 TTR monomers reduces the empty porous volume of the crystal that will be subsequently occupied by a secondary guest prone to optical sensing. Two secondary guests were tested. 318 One is cytochrome c that has similar molecular dimensions to the TTR monomer and was 319 320 already shown to almost fulfil the accessible void volume of MOF mesoporous crystals (Chen 321 et al. 2012). If the same trend is observed with TLN-CLC crystals - almost complete occupation of the free void volume – it provides an indirect method to quantify monomeric TTR 322 323 extraction. Cytochrome c catalyses a colorimetric reaction, and the initial velocity of the reaction catalysed by the crystals was used to access the crystal incorporation of this 324 enzyme. The other probe tested is fluorescein, that should diffuse freely through the large 325 pores of the TLN-CLC framework and equilibrate with the bulk solution concentration. 326 Fluorescence intensity of this compound enables facile quantification of the uptake extent. 327 328 The results of the assays that make use of the secondary probes are presented in Fig. 4 D and 329 E. The secondary probes are inverted indicators of the monomeric TTR uptake: crystals preincubated with the amyloidogenic variants show lower uptake of the secondary probe (due 330 to the occupation of the crystal void volume by monomeric TTR) when compared with the 331 ones incubated with the stable TTR variants, which agrees with the western blot analysis 332 (figure 3A). The assay is thus useful for facile and cheap sensing of monomers present in pure 333 recombinant TTR samples. The results with the two secondary probes show a similar trend; 334 there are not significant variations in the extraction of the three amyloidogenic variants 335 336 tested. Extraction of TTR-T119M monomers looks slightly lower than the TTR-WT, as 337 expected, due to the quaternary stabilizing role of this mutation.

338

All rights reserved. No reuse allowed without permission.





Fig. 4. TLN-CLC efficiently extract TTR monomer from amyloidogenic TTR samples up to 340 observable quantities. A. Optical image of TLN-CLC (scale bar 0.5 mm). B. Crystal structures 341 of TTR with one of the monomers highlighted in green (PDB 1Y1D (Gales et al. 2005)) and of 342 the TLN tetragonal framework (PDB 6N4Z (Harrison et al. 2019)). C. Western blotting analysis, 343 with an antibody targeting human TTR, of the uptake by TLN-CLC crystals of TTR variants 344 displaying a range of quaternary stability behaviours. D and E. Correlation between the 345 346 crystal free void volumes after incubation with several TTR variants, estimated with fluorescein and cytochrome c, respectively. F. A colorimetric reaction was used to estimate 347 cytochrome c trapped in the crystals (considered to be proportional to the reaction initial 348 velocities). Examples of reaction progression curves used to estimate initial velocities are 349 shown (color code of TTR variants in which the crystals were pre-incubated as in E. Three 350 independent experiments were performed for each condition. 351

352

353

3.3. TLN-CLC -based assay enables the evaluation the TTR drug candidates at nearly
physiologic conditions.

356 Small compounds, mostly binding in the TTR channel, are being developed to stabilize 357 the protein native structure and therefore inhibit TTR amyloid formation. This therapeutic 358 strategy is being persecuted for many years and, as a result, tafamidis became the first

compound approved for the treatment of TTR amyloidosis by the European Commission and
 the FDA. Here, we evaluated the protective effect of two TTR stabilizers, Tafamidis and
 Acoramidis, at nearly physiologic conditions.

Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds 362 363 TTR and kinetically stabilizes WT-TTR and mutant tetramers under denaturing and physiologic conditions, inhibiting amyloidogenesis (Bulawa et al. 2012). The authors 364 overcame the difficulty to detect monomeric species under physiologic conditions indirectly, 365 366 using subunit exchange experiments. A double-blind clinical trial demonstrated the efficacy 367 of tafamidis in slowing the progression of TTR (Coelho et al. 2012). Acoramidis (AG10), or 3-[3-(3,5-dimethyl-1h-pyrazol-4-Yl)propoxy]-4-fluorobenzoic acid, is another promising drug 368 369 that achieves near-complete stabilization of TTR in the plasma (Judge et al. 2019). It is currently in clinical trials for the treatment of TTR Amyloidosis (Fox et al. 2020). 370

371 The amyloidogenic proteins variants TTR-L55P and TTR-Y78F were used, and experiments were performed with drug / TTR molar ratios of 10/1, 1/1 and 0/1. The results 372 are presented in Fig. 5. The two molecular probes (cytochrome c and fluorescein) used to 373 374 estimate crystal void volumes yielded similar results (no statistically significant differences 375 observed). In general, there was a significant reduction in the dissociation into monomers after addition of equimolar concentration of the drug; increasing 10x the concentration of 376 the drug further increases the stability of the tetramer at physiological conditions. A drug / 377 378 TTR molar ratio of 10/1, but not of 1/1, yielded dissociation rates equivalent to the TTR-WT. The assay is not sensible enough to detect significant differences between the action of 379 380 tafamidis and acoramidis. Also, a consistent drug stabilizing effect was observed towards the 381 two amyloidogenic variants.

382



- 384 Fig. 5. Application of TLN-CLC-based assay for evaluation of TTR stabilizers at nearly physiological conditions. Two drugs were tested, tafamidis (top) and acoramidis (bottom), 385 386 with the amyloidogenic variants TTR-L55P and TTR-Y78F. Drug / TTR molar ratio: 10 /1, 1/1 and 0/1. TTR monomer uptake estimated indirectly, using secondary probes cytochrome c 387 and fluorescein. Stability of the TTR variants is very sensitive do the drug / protein 388 389 stoichiometry; the two drugs show a similar activity with both TTR variants. Results from three independent experiments for each condition. 390
- 391

Thus, we devised an in vitro assay for facile evaluation of the effect of compounds on 392 393 TTR stability at physiologic pH. The assay outcomes the technical complexity of other indirect methods already in use, such as the determination of TTR subunit exchange rates (Nelson et 394 395 al. 2021). Moreover, the assay is very sensitive to the drug / protein stoichiometry. It also reveals that stabilizing effect of the two compounds tested, tafamidis and acoramidis, in the 396 amyloidogenic variants TTR-L55P and TTR-Y78F is very similar. 397

- 398
- 399

3.4. TLN-CLC - based assay reveals increased levels of TTR monomers in the plasma of TTR
amyloidosis patients.

Sensing monomeric TTR in plasma microsamples and proving the utility of the assay to
discriminate between carriers of amyloidogenic TTR variants and TTR-WT constitute the main
goal of this work. The TLN-CLC - based assay was tested with plasma samples of ten
individuals, five carriers of TTR-V30M (# 53, 55, 56. 61 and 69) and five healthy controls (#
51, 52, 54. 57 and 58).

TLN-CLC crystals were incubated in 5 µl plasma samples for 3 h and the protein uptake
analysed. We first checked by SDS analysis that unspecific adsorption of high molecular
weight plasma proteins in the external surface of TLN-CLC crystals was negligible (not
shown), providing a critical advantage towards the use of Tb-MOF crystals. This is crucial
because the immunosensing assay that will be used subsequently for quantification of TTR
collected from the crystals, does not efficiently discriminate between tetramers and
monomers.

Identification of the target protein in the crystals' extracts was accomplished by antiTTR Western blotting (Fig. 6A). Despite the variations observed in the monomeric TTR gel
band intensities among the samples of TTR-V30M carriers, imaging analysis shows that they
are significantly stronger than the ones of the controls. It should be noticed that semidenaturing conditions were used, which enables the detection of the dimeric TTR band when
a solution of TTR-WT is loaded (positive control). The TTR dimer is not detected in the crystal
extracts which confirms that TTR surface adsorption is negligible.

The monomeric TTR released from the TLN-CLC crystals, after incubation in plasma 421 samples, was analysed by ELISA (Fig, 6B). In addition, the ELISA assay was also used to 422 423 quantify the total concentration of TTR in plasma samples. It was observed that plasma TTR 424 concentration of the TTR-V30M carriers is lower than the one of healthy controls, a feature 425 already pointed for carriers of other amyloidogenic mutations such as TTR-V122I (Buxbaum et al. 2008). Moreover, it was also already noticed that age, gender and progression of the 426 disease influence in a statistically significant manner the serum TTR levels (Buxbaum et al. 427 2008), which, together with the small sample size used here, may contribute to 428 429 heterogeneity of the results. To exclude the effect of the variations in the levels of total

430 plasma TTR, we found more reliable to use the monomeric TTR / total TTR ratio instead of

the monomeric TTR alone. 431

432





444

The monomeric TTR / total TTR ratio was determined for the plasma samples of the 10 445 individuals (three independent experiments for each sample) and the results are presented 446 447 in Fig. 6B. TLN-CLC crystals extract a fraction of 10⁻⁴ to 10⁻³ of the total TTR in the plasma 448 samples. Comparison between the two groups of individuals, shows that the monomeric TTR / total TTR ratio of the TTR-V30M carriers is higher than normal in a statistically significant 449 450 manner. As expected, the difference towards the control group is bigger than the obtained by 451 anti-TTR Western blotting of the monomers (insets of Fig. 6A and B) due to the normalization 452 by the respective plasma concentration of total TTR. In line with our results, the presence of TTR oligomers circulating in the plasma of patients that are carriers of TTR-V30M in 453 454 concentrations above healthy controls was already detected using peptide probes (Schonhoft et al. 2017). According to the established TTR amyloid cascade, the oligomers are formed by 455 the self-assembly of monomers, not of native tetramers. 456

It is interesting to notice that no statistically significant variations were observed within the control group, an indication that the monomeric TTR / total TTR ratio eliminates gender and age caused variations, becoming a reliable indicator of disease progression. On the other hand, variations among the group of individuals carrying the TTR-V30M are much more pronounced, probably due to different stages in the disease progression within the group, a feature that could not be confirmed because the clinical state of the individuals carrying the amyloidogenic mutation was not disclosed.

464

465

466 **4. Conclusion**

Tetramer dissociation is the controlling step in TTR amyloidogenesis which prompted us
to develop an assay to detect variations in the concentration of circulating monomeric TTR.
The assay is technically simple to apply, demands a small volume of plasma sample (around 5 µl) and aims to sense a more suitable target (monomeric TTR) for early diagnosis and
accurate evaluation of any therapeutic intervention than standard techniques, which analyse
the deposition of amyloid aggregates. Moreover, the use of a fluid biomarker (circulating
monomeric TTR) eliminates the currently adopted invasive biopsies modalities.

474 The assay was tested with two groups of five individuals each, one composed by 475 carriers of TTR-V30M variant and the other by healthy controls. It was observed that TTR amyloidosis patients have significantly higher concentration of monomeric TTR than healthy 476 477 controls. Moreover, determination of monomeric TTR / total TTR ratio was found to be more reliable than that of monomeric TTR alone. This is because total TTR concentration varies 478 479 from individual to individual due to several factors, such as gender, age and the progression of the disease itself. The same is found in diagnostic of the Alzheimer's disease, in which the 480 concentration of the more aggressive amyloid beta peptide 1-42 in the cerebrospinal fluid 481 482 (CSF) is normalized by the basal production of amyloid beta peptide 1-40, that varies between individuals (Gales 2024). 483

484 Typical immunosensing assays rely on surface-capture of target molecules, but this 485 constraint limits specificity towards the monomeric over the tetrameric TTR. We thus used instead mesoporous crystalline materials, which usually display excellent molecular sieving 486 properties. While performing experiments with different materials we found much more 487 challenging to work with plasma samples than with pure recombinant TTR samples, due to 488 489 unspecific adsorption of plasma proteins to the external surface of the crystalline particles. In 490 our test conditions, surface adsorption was much more severe in case of hybrid metalorganic materials than with protein-based materials. The later enabled us to develop the 491 492 proposed assay. Implementation of the assay is facilitated by the availability from commercial 493 sources of the protein selected to construct the porous framework, thermolysin, and by the 494 ease to grow the crystals abundantly.

495 Quantification of monomeric TTR concentrations can be useful not only for aiding physicians in point-of-care diagnosis but also for following the response to emergent 496 497 therapies focused on the administration of TTR stabilizers. In this context, circulating 498 monomeric TTR should be the ideal response-to-treatment biomarker. Finally, we have also 499 developed an optical assay that can be used to evaluate TTR drug candidates in vitro under 500 nearly physiological conditions. This is an improvement towards standard methods that use 501 critical experimental conditions, such as low pH, and to other demanding methods used to assess the residual monomeric TTR levels observed at physiological pH. 502

- 503
- 504

505

506 Acknowledgements

507 This work was supported by National funds through FCT—Fundação para a Ciência e a

- 508 Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the
- 509 projects "Institute for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-
- 510 007274) and by European Union's Horizon 2020 research and innovation programme under
- 511 grant agreement No. 952334 (PhasAGE).
- 512 FCT is gratefully acknowledged for the PhD grant SFRH/BD/151016/2021 (to D.C.).
- 513 Protein production and purification performed at the i3S Biochemical and Biophysical
- 514 Technologies Platform. The mass spectrometry analysis done at the Proteomics i3S Scientific
- 515 Platform with the assistance of Hugo Osório and the support of the Portuguese Mass
- 516 Spectrometry Network (ROTEIRO/0028/2013; LISBOA-01-0145-FEDER-022125).

517

518

519 References

Abe, S., Tabe, H., Ijiri, H., Yamashita, K., Hirata, K., Atsumi, K., Shimoi, T., Akai, M., Mori, H., Kitagawa,
S., Ueno, T., 2017. Crystal Engineering of Self-Assembled Porous Protein Materials in Living Cells. ACS
Nano 11(3), 2410-2419.

523 Adams, D., Suhr, O.B., Hund, E., Obici, L., Tournev, I., Campistol, J.M., Slama, M.S., Hazenberg, B.P.,

524 Coelho, T., 2016. First European consensus for diagnosis, management, and treatment of

- transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 29 Suppl 1(Suppl 1), S14-26.
- Afonso, R.V., Durão, J., Mendes, A., Damas, A.M., Gales, L., 2010. Dipeptide crystals as excellent
 permselective materials: Sequential exclusion of argon, nitrogen, and oxygen. Angewandte Chemie International Edition 49(17), 3034-3036.
- Almeida, M.R., Alves, I.L., Terazaki, H., Ando, Y., Saraiva, M.J., 2000. Comparative studies of two
 transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and
- 531 TTR T119M. Biochem Biophys Res Commun 270(3), 1024-1028.
- Almeida, M.R., Gales, L., Damas, A.M., Cardoso, I., Saraiva, M.J., 2005. Small transthyretin (TTR)
- ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 4(5),587-596.
- 535 Benson, M.D., Waddington-Cruz, M., Berk, J.L., Polydefkis, M., Dyck, P.J., Wang, A.K., Planté-
- 536 Bordeneuve, V., Barroso, F.A., Merlini, G., Obici, L., Scheinberg, M., Brannagan, T.H., Litchy, W.J.,
- 537 Whelan, C., Drachman, B.M., Adams, D., Heitner, S.B., Conceição, I., Schmidt, H.H., Vita, G., Campistol,
- J.M., Gamez, J., Gorevic, P.D., Gane, E., Shah, A.M., Solomon, S.D., Monia, B.P., Hughes, S.G., Jesse
- 539 Kwoh, T., McEvoy, B.W., Jung, S.W., Baker, B.F., Ackermann, E.J., Gertz, M.A., Coelho, T., 2018.
- 540 Inotersen treatment for patients with Hereditary transthyretin amyloidosis. New England Journal of
- 541 Medicine 379(1), 22-31.

- All rights reserved. No reuse allowed without permission.
- 542 Bonifácio, M.J., Sakaki, Y., Saraiva, M.J., 1996. 'In vitro' amyloid fibril formation from transthyretin:
- 543 The influence of ions and the amyloidogenicity of TTR variants. Biochimica et Biophysica Acta -
- 544 Molecular Basis of Disease 1316(1), 35-42.
- 545 Bulawa, C.E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J.A., Packman, J., Powers, E.T.,

546 Wiseman, R.L., Foss, T.R., Wilson, I.A., Kelly, J.W., Labaudinière, R., 2012. Tafamidis, a potent and

547 selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National

- 548 Academy of Sciences of the United States of America 109(24), 9629-9634.
- 549 Buxbaum, J., Koziol, J., Connors, L.H., 2008. Serum transthyretin levels in senile systemic amyloidosis: 550 effects of age, gender and ethnicity. Amyloid 15(4), 255-261.
- 551 Chen, Y., Lykourinou, V., Vetromile, C., Hoang, T., Ming, L.J., Larsen, R.W., Ma, S., 2012. How can
- proteins enter the interior of a MOF? investigation of cytochrome c translocation into a MOF
 consisting of mesoporous cages with microporous windows. Journal of the American Chemical
 Society 134(32), 13188-13191.
- 555 Coelho, T., Maia, L.F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P.,
- 556 Suhr, O.B., Campistol, J.M., Conceição, I.M., Schmidt, H.H., Trigo, P., Kelly, J.W., Labaudinière, R., Chan,
- J., Packman, J., Wilson, A., Grogan, D.R., 2012. Tafamidis for transthyretin familial amyloid
- 558 polyneuropathy: a randomized, controlled trial. Neurology 79(8), 785-792.
- 559 Comotti, A., Bracco, S., Distefano, G., Sozzani, P., 2009. Methane, carbon dioxide and hydrogen 560 storage in nanoporous dipeptide-based materials. Chemical Communications(3), 284-286.
- 561 Cvetkovic, A., Picioreanu, C., Straathof, A.J.J., Krishna, R., Van Der Wielen, L.A.M., 2005. Relation
- 562 between pore sizes of protein crystals and anisotropic solute diffusivities. Journal of the American
- 563 Chemical Society 127(3), 875-879.
- 564 Dong, X., Zhao, G., Li, X., Fang, J., Miao, J., Wei, Q., Cao, W., 2020. Electrochemiluminescence
 565 immunosensor of "signal-off" for beta-amyloid detection based on dual metal-organic frameworks.
 566 Talanta 208, 120376.
- 567 Durão, J., Gales, L., 2013. Guest diffusion in dipeptide crystals. CrystEngComm 15(8), 1532-1535.
- Fox, J.C., Hellawell, J.L., Rao, S., O'Reilly, T., Lumpkin, R., Jernelius, J., Gretler, D., Sinha, U., 2020. Firstin-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the
- Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and
 Pharmacodynamic Study in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development
- 571 Pharmacodynamic Study ir 572 9(1), 115-129.
 - 573 Furuya, H., Saraiva, M.J.M., Gawinowicz, M.A., Alves, I.L., Costa, P.P., Sasaki, H., Goto, I., Sakaki, Y.,
- 574 1991. Production of recombinant human transthyretin with biological activities toward the
- understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry30(9), 2415-2421.
- 577 Gales, L., 2019. Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of 578 Adult Patients with Hereditary Transthyretin Amyloidosis. Pharmaceuticals (Basel) 12(2).
- 579 Gales, L., 2024. Detection and clearance in Alzheimer's disease: leading with illusive chemical,
 580 structural and morphological features of the targets. Neural Regeneration Research 19(3), 497-498.
- 581 Gales, L., Macedo-Ribeiro, S., Arsequell, G., Valencia, G., Saraiva, M.J., Damas, A.M., 2005. Human
- transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid
 inhibitor. Biochemical Journal 388(2), 615-621.

- All rights reserved. No reuse allowed without permission.
- 584 Görbitz, C.H., 2001. Nanotube formation by hydrophobic dipeptides. Chemistry A European Journal 585 7(23), 5153-5159.
- 586 Gu, C., Liu, Y., Hu, B., Liu, Y., Zhou, N., Xia, L., Zhang, Z., 2020. Multicomponent nanohybrids of
- nickel/ferric oxides and nickel cobaltate spinel derived from the MOF-on-MOF nanostructure as
 efficient scaffolds for sensitively determining insulin. Anal. Chim. Acta 1110, 44-55.
- 589 Harrison, K., Wu, Z., Juers, D.H., 2019. A comparison of gas stream cooling and plunge cooling of 590 macromolecular crystals. Journal of Applied Crystallography 52(5), 1222-1232.
- Hashimoto, T., Ye, Y., Matsuno, A., Ohnishi, Y., Kitamura, A., Kinjo, M., Abe, S., Ueno, T., Yao, M.,
- 592 Ogawa, T., Matsui, T., Tanaka, Y., 2019. Encapsulation of biomacromolecules by soaking and co-
- 593 crystallization into porous protein crystals of hemocyanin. Biochemical and Biophysical Research594 Communications 509(2), 577-584.
- Hausrath, A.C., Matthews, B.W., 2002. Thermolysin in the absence of substrate has an open
 conformation. Acta Crystallographica Section D 58(6 Part 2), 1002-1007.
- Judge, D.P., Heitner, S.B., Falk, R.H., Maurer, M.S., Shah, S.J., Witteles, R.M., Grogan, M., Selby, V.N.,
- Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, S., Sinha, U., Turtle, C.W., Fox, J.C., 2019.
- 599 Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. Journal of 600 the American College of Cardiology 74(3), 285-295.
- Juers, D.H., Farley, C.A., Saxby, C.P., Cotter, R.A., Cahn, J.K.B., Holton-Burke, R.C., Harrison, K., Wu, Z.,
 2018. The impact of cryosolution thermal contraction on proteins and protein crystals: volumes,
 conformation and order. Acta Crystallographica Section D 74(9), 922-938.
- Juers, D.H., Ruffin, J., 2014. MAP-CHANNELS: A computation tool to aid in the visualization and
 characterization of solvent channels in macromolecular crystals. Journal of Applied Crystallography
 47(6), 2105-2108.
- Kim, J.H., Oroz, J., Zweckstetter, M., 2016. Structure of Monomeric Transthyretin Carrying the
 Clinically Important T119M Mutation. Angewandte Chemie International Edition 55(52), 1616816171.
- Kowalski, A.E., Johnson, L.B., Dierl, H.K., Park, S., Huber, T.R., Snow, C.D., 2019. Porous protein crystals
 as scaffolds for enzyme immobilization. Biomaterials Science 7(5), 1898-1904.
- Lai, Y.T., Reading, E., Hura, G.L., Tsai, K.L., Laganowsky, A., Asturias, F.J., Tainer, J.A., Robinson, C.V.,
- Yeates, T.O., 2014. Structure of a designed protein cage that self-assembles into a highly porous cube.Nat Chem 6(12), 1065-1071.
- Leite, J.P., Figueira, F., Mendes, R.F., Almeida Paz, F.A., Gales, L., 2023. Metal–Organic Frameworks as
 Sensors for Human Amyloid Diseases. ACS Sensors 8(3), 1033-1053.
- Leite, J.P., Gales, L., 2019. Alzheimer's Aβ1-40 peptide degradation by thermolysin: evidence of
 inhibition by a C-terminal Aβ product. FEBS Letters 593(1), 128-137.
- Leite, J.P., Rodrigues, D., Ferreira, S., Figueira, F., Almeida Paz, F.A., Gales, L., 2019. Mesoporous
 Metal–Organic Frameworks as Effective Nucleating Agents in Protein Crystallography. Crystal Growth
- 621 & Design 19(3), 1610-1615.
- Mendes, R.F., Figueira, F., Leite, J.P., Gales, L., Almeida Paz, F.A., 2020. Metal-organic frameworks: a
 future toolbox for biomedicine? Chem Soc Rev 49(24), 9121-9153.
- 624 Nelson, L.T., Paxman, R.J., Xu, J., Webb, B., Powers, E.T., Kelly, J.W., 2021. Blinded potency comparison
- of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid 28(1), 24-29.

All rights reserved. No reuse allowed without permission.

- Parakra, R.D., Kleffmann, T., Jameson, G.N.L., Ledgerwood, E.C., 2018. The proportion of Met80sulfoxide dictates peroxidase activity of human cytochrome c. Dalton Transactions 47(27), 9128-9135.
- 628 Park, Y.K., Sang, B.C., Kim, H., Kim, K., Won, B.H., Choi, K., Choi, J.S., Ahn, W.S., Won, N., Kim, S., Dong,
- H.J., Choi, S.H., Kim, G.H., Cha, S.S., Young, H.J., Jin, K.Y., Kim, J., 2007. Crystal structure and guest
- 630 uptake of a mesoporous metal-organic framework containing cages of 3.9 and 4.7 nm in diameter.
- Angewandte Chemie International Edition 46(43), 8230-8233.
- 632 Pletzer-Zelgert, J., Ehrt, C., Fender, I., Griewel, A., Flachsenberg, F., Klebe, G., Rarey, M., 2023.
- 633 LifeSoaks: A tool for analyzing solvent channels in protein crystals and obstacles for soaking
- experiments. Acta Crystallographica Section D: Structural Biology 79, 837-856.
- Redondo, C., Damas, A.M., Olofsson, A., Lundgren, E., Saraiva, M.J.M., 2000. Search for intermediate
 structures in transthyretin fibrillogenesis: Soluble tetrameric Tyr78Phe TTR expresses a specific
- epitope present only in amyloid fibrils. Journal of Molecular Biology 304(3), 461-470.
- 638 Schonhoft, J.D., Monteiro, C., Plate, L., Eisele, Y.S., Kelly, J.M., Boland, D., Parker, C.G., Cravatt, B.F.,
- 639 Teruya, S., Helmke, S., Maurer, M., Berk, J., Sekijima, Y., Novais, M., Coelho, T., Powers, E.T., Kelly, J.W.,
- 640 2017. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis
- 641 patients. Science Translational Medicine 9(407).
- 642 Sheta, S.M., El-Sheikh, S.M., Abd-Elzaher, M.M., 2019. A novel optical approach for determination of 643 prolactin based on Pr-MOF nanofibers. Anal. Bioanal. Chem. 411(7), 1339-1349.
- Song, X., Shao, X., Dai, L., Fan, D., Ren, X., Sun, X., Luo, C., Wei, Q., 2020. Triple Amplification of
- 3,4,9,10-Perylenetetracarboxylic Acid by Co(2+)-Based Metal-Organic Frameworks and Silver-Cysteine
 and Its Potential Application for Ultrasensitive Assay of Procalcitonin. ACS Appl. Mater. Interfaces
 12(8), 9098-9106.
- Tajahmadi, S., Molavi, H., Ahmadijokani, F., Shamloo, A., Shojaei, A., Sharifzadeh, M., Rezakazemi, M.,
 Fatehizadeh, A., Aminabhavi, T.M., Arjmand, M., 2023. Metal-organic frameworks: A promising option
 for the diagnosis and treatment of Alzheimer's disease. Journal of Controlled Release 353, 1-29.
- Vilenchik, L.Z., Griffith, J.P., St. Clair, N., Navia, M.A., Margolin, A.L., 1998. Protein Crystals as Novel
 Microporous Materials. Journal of the American Chemical Society 120(18), 4290-4294.
- Wang, Z., Hu, X., Sun, N., Deng, C., 2019. Aptamer-functionalized magnetic metal organic framework
 as nanoprobe for biomarkers in human serum. Anal. Chim. Acta 1087, 69-75.
- Wu, Q., Tan, R., Mi, X., Tu, Y., 2020. Electrochemiluminescent aptamer-sensor for alpha synuclein
 oligomer based on a metal-organic framework. Analyst 145(6), 2159-2167.
- 657 Zhou, Y., Li, C., Li, X., Zhu, X., Ye, B., Xu, M., 2018. A sensitive aptasensor for the detection of β-
- amyloid oligomers based on metal–organic frameworks as electrochemical signal probes. Anal.
- 659 Methods 10(36), 4430-4437.